Kairos Pharma Ltd./$KAPA
1D1W1MYTD1Y5YMAX
About Kairos Pharma Ltd.
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
- Ticker
- $KAPA
- Sector
- Health
- Primary listing
- AMEX
- Employees
- -
- Headquarters
- Los Angeles, United States
- Website
- kairospharma.com
KAPA Metrics
BasicAdvanced
$5.6M
-
-$0.28
-
-
Price and volume
Market cap
$5.6M
52-week high
$2.11
52-week low
$0.22
Average daily volume
1.7M
Financial strength
Current ratio
11.977
Quick ratio
9.909
Profitability
EBITDA (TTM)
-5.815
Management effectiveness
Return on assets (TTM)
-66.91%
Return on equity (TTM)
-113.96%
Valuation
Price to book
1.21
Price to tangible book (TTM)
1.21
Price to free cash flow (TTM)
-1.247
Free cash flow yield (TTM)
-80.20%
Free cash flow per share (TTM)
-0.19
Growth
Earnings per share change (TTM)
-16.02%
3-year earnings per share growth (CAGR)
52.29%
KAPA News
AllArticlesVideos
Kairos Pharma Announces 1-for-7 Reverse Stock Split
Business Wire1 week ago
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
Business Wire1 month ago
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever
Newsfile Corp2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.